| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print October 24, 2001
J. Biol. Chem, 10.1074/jbc.M108931200
Submitted on September 17, 2001
Revised on October 24, 2001
Accepted on October 22, 2001
Department of Biochemistry, Case Western Reserve University, Cleveland, OH 44106
Corresponding Author: hxk43{at}po.cwru.edu
Acetylation of histone core particles play an important role in modulating chromatin structure and gene expression. The acetylation status of the histone tails is determined by two opposing enzymatic activities: histone acetyltransferases (HATs) and histone deacetylases (HDACs). Here we describe the isolation and characterization of HDAC10, a novel class II histone deacetylase. Molecular cloning and Northern blot analyses reveal that the HDAC10 transcript is widely expressed and subjected to alternative splicing. HDAC10 is both nuclear and cytoplasmic, a feature reminiscent of HDAC4, -5, and -7. Distinct from other family members, HDAC10 harbors an amino-terminal catalytic domain and a carboxyl pseudo-repeat that shares significant homology with its catalytic domain. Mutational analysis reveals that transcriptional repression by HDAC10 requires its intrinsic histone deacetylase activity. Taken together, HDAC10 represents a distinct HDAC that may play a role in transcription regulation.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Gao, X. Cheng, M. Lam, Y. Liu, Q. Liu, K.-S. Chang, and H.-Y. Kao Signal-dependent Regulation of Transcription by Histone Deacetylase 7 Involves Recruitment to Promyelocytic Leukemia Protein Nuclear Bodies Mol. Biol. Cell, July 1, 2008; 19(7): 3020 - 3027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fournel, C. Bonfils, Y. Hou, P. T. Yan, M.-C. Trachy-Bourget, A. Kalita, J. Liu, A.-H. Lu, N. Z. Zhou, M.-F. Robert, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo Mol. Cancer Ther., April 1, 2008; 7(4): 759 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Fukuda, N. Sano, S. Muto, and M. Horikoshi Simple histone acetylation plays a complex role in the regulation of gene expression. Brief Funct Genomic Proteomic, September 1, 2006; 5(3): 190 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xu, P. K. Sengupta, E. Seto, and B. D. Smith Regulatory Factor for X-box Family Proteins Differentially Interact with Histone Deacetylases to Repress Collagen {alpha}2(I) Gene (COL1A2) Expression J. Biol. Chem., April 7, 2006; 281(14): 9260 - 9270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Yoo, J.-J. Chung, S. S. Choe, K. H. Kim, and J. B. Kim Down-regulation of Histone Deacetylases Stimulates Adipocyte Differentiation J. Biol. Chem., March 10, 2006; 281(10): 6608 - 6615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Mukhopadhyay, E. Weisberg, D. Gilchrist, R. Bueno, D. J. Sugarbaker, and M. T. Jaklitsch Effectiveness of Trichostatin A as a Potential Candidate for Anticancer Therapy in Non-Small-Cell Lung Cancer. Ann. Thorac. Surg., March 1, 2006; 81(3): 1034 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-J. Yang and S. Gregoire Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication Mol. Cell. Biol., April 15, 2005; 25(8): 2873 - 2884. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Waltregny, L. de Leval, W. Glenisson, S. Ly Tran, B. J. North, A. Bellahcene, U. Weidle, E. Verdin, and V. Castronovo Expression of Histone Deacetylase 8, a Class I Histone Deacetylase, Is Restricted to Cells Showing Smooth Muscle Differentiation in Normal Human Tissues Am. J. Pathol., August 1, 2004; 165(2): 553 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hu, E. Dul, C.-M. Sung, Z. Chen, R. Kirkpatrick, G.-F. Zhang, K. Johanson, R. Liu, A. Lago, G. Hofmann, et al. Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 720 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Davie Inhibition of Histone Deacetylase Activity by Butyrate J. Nutr., July 1, 2003; 133(7): 2485S - 2493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ju and M. T. Muller Histone Deacetylase Inhibitors Activate p21WAF1 Expression via ATM Cancer Res., June 1, 2003; 63(11): 2891 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Berger, C. Bieniossek, C. Schaffitzel, M. Hassler, E. Santelli, and T. J. Richmond Direct Interaction of Ca2+/Calmodulin Inhibits Histone Deacetylase 5 Repressor Core Binding to Myocyte Enhancer Factor 2 J. Biol. Chem., May 9, 2003; 278(20): 17625 - 17635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Petrie, F. Guidez, L. Howell, L. Healy, S. Waxman, M. Greaves, and A. Zelent The Histone Deacetylase 9 Gene Encodes Multiple Protein Isoforms J. Biol. Chem., April 25, 2003; 278(18): 16059 - 16072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. THIAGALINGAM, K.-H. CHENG, H. J. LEE, N. MINEVA, A. THIAGALINGAM, and J. F. PONTE Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code Ann. N.Y. Acad. Sci., March 1, 2003; 983(1): 84 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. De Schepper, H. Bruwiere, T. Verhulst, U. Steller, L. Andries, W. Wouters, M. Janicot, J. Arts, and J. Van heusden Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 881 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Glaser, M. J. Staver, J. F. Waring, J. Stender, R. G. Ulrich, and S. K. Davidsen Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines Mol. Cancer Ther., February 1, 2003; 2(2): 151 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Ding, L. L. Gillespie, and G. D. Paterno Human MI-ER1 Alpha and Beta Function as Transcriptional Repressors by Recruitment of Histone Deacetylase 1 to Their Conserved ELM2 Domain Mol. Cell. Biol., January 1, 2003; 23(1): 250 - 258. [Abstract] [Full Text]
|
|
|
|
|
|
J. J. Westendorf, S. K. Zaidi, J. E. Cascino, R. Kahler, A. J. van Wijnen, J. B. Lian, M. Yoshida, G. S. Stein, and X. Li Runx2 (Cbfa1, AML-3) Interacts with Histone Deacetylase 6 and Represses the p21CIP1/WAF1 Promoter Mol. Cell. Biol., November 15, 2002; 22(22): 7982 - 7992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Butler, X. Zhou, W.-S. Xu, H. I. Scher, R. A. Rifkind, P. A. Marks, and V. M. Richon The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin PNAS, September 3, 2002; 99(18): 11700 - 11705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fournel, M.-C. Trachy-Bourget, P. T. Yan, A. Kalita, C. Bonfils, C. Beaulieu, S. Frechette, S. Leit, E. Abou-Khalil, S.-H. Woo, et al. Sulfonamide Anilides, a Novel Class of Histone Deacetylase Inhibitors, Are Antiproliferative against Human Tumors Cancer Res., August 1, 2002; 62(15): 4325 - 4330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. David, M. A. Neptune, and R. A. DePinho SUMO-1 Modification of Histone Deacetylase 1 (HDAC1) Modulates Its Biological Activities J. Biol. Chem., June 21, 2002; 277(26): 23658 - 23663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lemercier, M.-P. Brocard, F. Puvion-Dutilleul, H.-Y. Kao, O. Albagli, and S. Khochbin Class II Histone Deacetylases Are Directly Recruited by BCL6 Transcriptional Repressor J. Biol. Chem., June 7, 2002; 277(24): 22045 - 22052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Hartman, X. Hu, K. X. Tyler, C. K. Dalal, and M. A. Lazar Mechanisms Regulating Adipocyte Expression of Resistin J. Biol. Chem., May 24, 2002; 277(22): 19754 - 19761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Tong, J. Liu, N. R. Bertos, and X.-J. Yang Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain Nucleic Acids Res., March 1, 2002; 30(5): 1114 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Richon and J. P. O'Brien Histone Deacetylase Inhibitors: A New Class of Potential Therapeutic Agents for Cancer Treatment : Commentary re: V. Sandor et al., Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with Refractory Neoplasms. Clin. Cancer Res., 8: 718-728, 2002. Clin. Cancer Res., March 1, 2002; 8(3): 662 - 664. [Full Text] [PDF]
|
|
|
|
|
|
D. D. Fischer, R. Cai, U. Bhatia, F. A. M. Asselbergs, C. Song, R. Terry, N. Trogani, R. Widmer, P. Atadja, and D. Cohen Isolation and Characterization of a Novel Class II Histone Deacetylase, HDAC10 J. Biol. Chem., February 15, 2002; 277(8): 6656 - 6666. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
